Zymeworks (ZYME) Reiterated at Buy by Stifel: 'Significantly Undervalued'

June 29, 2026 7:19 AM

Stifel analyst Stephen Willey reiterated a Buy rating and $47.00 price target on Zymeworks (NASDAQ: ZYME).The analyst commented, "We recently ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found